China SXT Pharmaceuticals (FRA:2RY1) ROCE %: 1.55% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2RY1 China SXT Pharmaceuticals Inc FRA:2RY1
40 GF Score
Price €0.04
GF Value €1.16
! 8 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals ROCE %?

China SXT Pharmaceuticals FRA:2RY1 40 ROCE % is 1.55% as of Mar. 2026. GuruFocus rates FRA:2RY1 with a GF Score™ of 40/100 and a GF Value™ of €1.16. The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China SXT Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.55%.

China SXT Pharmaceuticals  (FRA:2RY1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China SXT Pharmaceuticals ROCE % Related Terms

China SXT Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals ROCE % Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.43 -35.19 -17.31 -17.82 -26.06

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138.09 -5.57 -18.14 -67.80 1.55
FRA:2RY1
40GF Score
China SXT Pharmaceuticals Inc FRA:2RY1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals ROCE % Calculation

China SXT Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-5.313/( ( (20.039 - 5.561) + (30.063 - 3.762) )/ 2 )
=-5.313/( (14.478+26.301)/ 2 )
=-5.313/20.3895
=-26.06 %

China SXT Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=0.338/( ( (22.453 - 5.079) + (30.063 - 3.762) )/ 2 )
=0.338/( ( 17.374 + 26.301 )/ 2 )
=0.338/21.8375
=1.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.55% mean?
China SXT Pharmaceuticals (FRA:2RY1) has a ROCE % of 1.55% as of Mar. 2026.
Is China SXT Pharmaceuticals' ROCE % too high?
China SXT Pharmaceuticals' current ROCE % is 1.55%. The Drug Manufacturers industry median ROCE % is 7.05. China SXT Pharmaceuticals' value of 1.55% is 78% below this industry median. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' ROCE % compare to CABR and BFRI?
China SXT Pharmaceuticals' ROCE % of 1.55% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.05. China SXT Pharmaceuticals' value of 1.55% is 78% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.05, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current ROCE % of 1.55% is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current ROCE % is 1.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current ROCE % of 1.55%. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current ROCE % is 1.55% and 78% below the Drug Manufacturers industry median of 7.05. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current ROCE % is 1.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued. The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.

Key valuation signals for FRA:2RY1:

  • ROCE %: 1.55%
  • GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
  • GF Score™: 40/100 with 8 warning signs
  • Industry Position: 78% below the Drug Manufacturers median

No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score

Get the complete analysis for FRA:2RY1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€1.16
GF Value